STAAR Surgical Company has outlined its financial expectations for the fiscal year 2025, specifically highlighting anticipated improvements in China during the latter half of the year. The company foresees a sluggish start with minimal sales of Implantable Collamer Lenses (ICLs) due to high inventory levels and soft demand. However, STAAR projects a potential upswing, estimating ICL sales could hit between $75 million and $125 million in the second half, influenced by the performance of refractive procedures in China.
Supporting this positive outlook is the planned mid-year launch of the EVO Plus lens, which is anticipated to have a higher average selling price. This strategic move might bolster revenue as it aligns with STAAR's focus on reducing import risks by keeping additional inventory within China, considering the geopolitical uncertainties and tariffs that could affect supply chains.
Beyond China, STAAR Surgical expects global ICL sales, excluding the Chinese market, to land between $165 million and $175 million, marking a growth of 9% to 15% from the previous year. While the company's forecasts hinge on current market conditions, various factors such as government policies and shifts in consumer demand could impact these projections. As reported by STAAR's official communications, these strategies reflect a concerted effort to navigate and capitalize on market dynamics globally.